Smile Digital Health Joins NCQA’s Digital Content Services Early Adopters Program to Support the Digitization of HEDIS Scores

1 year ago

Smile Digital Health is contributing insights and best practices for the digitization of HEDIS® scores as part of the NCQA…

Lexaria’s GLP-1 Human Pilot Study #3 Begins Dosing

1 year ago

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024…

Institute for Healthcare Advancement Announces Two Platforms to Help Amplify Health Literacy and Health Equity Adoption in Healthcare During Health Literacy Month

1 year ago

Both IHA platforms empower individuals with health literacy knowledge and skills to help those they serve make informed health decisions…

Hurricane Helene and Milton Devastation: Supporting Impacted Healthcare Professionals and Medical Facilities

1 year ago

OMAHA, NE / ACCESSWIRE / October 9, 2024 / As a company focused on supporting healthcare professionals, medical facilities, and…

MedCana Highlights Recent Acquisitions and the Multiple Cannabis Licenses Associated with Each

1 year ago

The licenses will add $1.6 million to our total Assets for the 3rd Quarter. AUSTIN, TX / ACCESSWIRE / October…

180 Life Sciences Corp. Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Rule and Expands into the Global iGaming Sector

1 year ago

PALO ALTO, CA / ACCESSWIRE / October 9, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180"), is…

Releaf & SOMAÍ Unite in Exclusive UK Cannabis Deal

1 year ago

Releaf® Announces Partnership with SOMAÍ Pharmaceuticals to Bring Innovative Cannabis Solutions to UK Patients NOTTINGHAM, ENGLAND / ACCESSWIRE / October…

Releaf & SOMAÍ Unite in Exclusive UK Cannabis Deal

1 year ago

Releaf® Announces Partnership with SOMAÍ Pharmaceuticals to Bring Innovative Cannabis Solutions to UK Patients NOTTINGHAM, ENGLAND / ACCESSWIRE / October…

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

1 year ago

– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and…